Cogent Biosciences (COGT) Current Assets (2017 - 2026)

Cogent Biosciences' Current Assets history runs 10 years deep, the most recent figure standing at $877.8 million for Q1 2026.

• In Q1 2026, Current Assets rose 247.12% year-over-year to $877.8 million; the TTM figure through Mar 2026 stood at $877.8 million (up 247.12% YoY), while the FY2025 annual figure was $910.4 million, up 207.06% from the prior year.
• Current Assets was $877.8 million for Q1 2026 at Cogent Biosciences, down from $910.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $910.4 million in Q4 2025 to a low of $194.7 million in Q1 2022.
• Historically, Current Assets has averaged $372.8 million across 5 years, with a median of $296.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Current Assets slumped 42.77% in 2025, then soared 247.12% in 2026.
• A 5-year view of Current Assets shows it stood at $265.0 million in 2022, then rose by 2.19% to $270.8 million in 2023, then climbed by 9.49% to $296.5 million in 2024, then jumped by 207.06% to $910.4 million in 2025, then dropped by 3.58% to $877.8 million in 2026.
• The last three Current Assets figures came in at $877.8 million (Q1 2026), $910.4 million (Q4 2025), and $397.2 million (Q3 2025), per Business Quant data.